Open Access<p>Therapeutic Effect of C-C Chemokine Receptor Type 1 (CCR1) Antagonist BX471 on Allergic Rhinitis</p>
Author(s) -
Suoyi Feng,
Longzhu Ju,
Ziqi Shao,
M.W. Grzanna,
Longfei Jia,
Ming Liu
Publication year - 2020
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s254717
Subject(s) - proinflammatory cytokine , eosinophil , chemokine , allergic inflammation , immunology , immunoglobulin e , cc chemokine receptors , chemistry , tumor necrosis factor alpha , chemokine receptor , microbiology and biotechnology , inflammation , medicine , biology , antibody , asthma
Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammatory respiratory hypersensitivity characterized by elevated Th2 cytokines and infiltration of inflammatory cells to nasal tissues. BX471 is a small-molecule C-C chemokine receptor type 1 (CCR1) antagonist involved in suppression of inflammation via blocking of primary ligands. In this study, we examined the anti-inflammatory effect of BX471 on ovalbumin (OVA)-induced AR mice model.